Top Research Reports For Bristol-Myers, BHP & CVS
Zacks Investment Research | Mar 23, 2020 01:53AM ET
Monday, March 23, 2020
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb (BMY), BHP Group (BHP) and CVS Health (NYSE:CVS) (CVS). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
Bristol-Myers’ shares have outperformed the Zacks Large Cap Pharmaceuticals over the past six months (-3.2% vs. -11.9%). The Zacks analyst believes that Bristol-Myers’ blockbuster immuno-oncology drug, Opdivo, and Eliquis have maintained the company’s momentum. Label expansion of Opdivo into additional indications should further boost the top line.
Empliciti and Sprycel are also performing well on label expansions. Blood thinner drug, Eliquis, is expected to drive further growth, propelled by increased share in the NOAC market. Meanwhile, the acquisition of Celgene (NASDAQ:CELG) has strengthened the company’s oncology portfolio with the addition Revlimid.
The acquisition will also strengthen the company’s pipeline with encouraging candidates. However, concerns will rise once Revlimid loses patent protection. Moreover, the company is facing headwinds like stiff competition from other immuno-oncology drugs and pipeline setbacks.
(You can )
Shares of BHP have lost 40.3% over the past year against the Zacks Mining - Miscellaneous industry’s fall of 38.7%. The Zacks analyst believes that BHP Group’s strong cash flow and focus on lowering debt are likely to enhance its capability.
The company maintains capital and exploration expenditure guidance below $8 billion for fiscal 2020 and $8 billion for fiscal 2021. It currently has six major projects under development in petroleum, copper, iron ore and potash. Efforts to make operations more efficient on the back of smarter technology adoption across the entire value chain will drive growth.
However, slowdown in global growth and lower commodity prices due to the coronavirus outbreak is likely to impact results. The consensus estimate for earnings for the current fiscal has undergone negative revision lately. Nevertheless, even though metal prices remain subdued in the near term, it will eventually pick up on the back of the impending demand-supply imbalance.
Get The News You Want
(You can )
CVS Health’s shares have lost 26.6% over the past three months against the Zacks Retail Pharmacies and Drug Stores industry’s fall of 25.1%. The Zacks analyst believes that the company’s recently-introduced Health Care Benefits segment, following the Aetna (NYSE:AET) acquisition, holds immense promise.
Additionally, solid year-over-year Retail/LTC comparisons were impressive. Strong expansion of both margins further buoys optimism on the stock. The expansions of MinuteClinics and HealthHUBs during the quarter are also encouraging. CVS Health ended the fourth quarter with better-than-expected numbers. However, the LTC business is facing some industry-wide challenges. Reimbursement risk continues to be a dampener.
(You can )
Other noteworthy reports we are featuring today include T-Mobile US (NASDAQ:TMUS) (TMUS), Southern (SO) and Anthem (NYSE:ANTM) (ANTM).
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly
Today's Must Read/h6
Featured Reports/h6
Per the Zacks analyst, T-Mobile is poised to benefit from the merger with Sprint, while it continues to deploy 600 MHz spectrum.
The Zacks analyst believes that steady increase in Southern Company (NYSE:SO)'s regulated business customer base should support its revenues.
Per the Zacks analyst, the company has been gaining traction from its rise in Medical membership over the past few quarters.
Strong prospect in Intutive Surgical's robotic platform - da Vinci System - is a positive. However, the Zacks analyst is apprehensive about cutthroat competition in the MedTech space.
Per the Zacks analyst, Mitsubishi UFJ has been growing through acquisitions and focus on its business upgradation plan (2018-2021).
Per the Zacks analyst, Infosys is benefiting from higher investments by clients in digital transformation, AI, automation and large deal wins.
Per the Zacks analyst, Analog Devices is benefiting from strengthening momentum of Battery Management System solutions in electric vehicles.
Per the Zacks analyst, T-Mobile is poised to benefit from the merger with Sprint, while it continues to deploy 600 MHz spectrum.
The Zacks analyst believes that steady increase in Southern Company (NYSE:SO)'s regulated business customer base should support its revenues.
Per the Zacks analyst, the company has been gaining traction from its rise in Medical membership over the past few quarters.
Strong prospect in Intutive Surgical's robotic platform - da Vinci System - is a positive. However, the Zacks analyst is apprehensive about cutthroat competition in the MedTech space.
Per the Zacks analyst, Mitsubishi UFJ has been growing through acquisitions and focus on its business upgradation plan (2018-2021).
Per the Zacks analyst, Infosys is benefiting from higher investments by clients in digital transformation, AI, automation and large deal wins.
Per the Zacks analyst, Analog Devices is benefiting from strengthening momentum of Battery Management System solutions in electric vehicles.
New Upgrades/h6
Per the Zacks analyst, Moderna's recent foray into development of mRNA-based vaccine for coronavirus infection, COVID-19, and rapid progress with it is boosting the company's prospects.
Per the Zacks analyst, Enphase's microinverters are enjoying solid demand with rising solar rooftop installations. It can capture larger shares of the booming solar market with its latest innovations.
Per the Zacks analyst, Hawaiian Electric's systematic investments in utility infrastructure development help it to meet increasing consumer demand.
Per the Zacks analyst, Moderna's recent foray into development of mRNA-based vaccine for coronavirus infection, COVID-19, and rapid progress with it is boosting the company's prospects.
Per the Zacks analyst, Enphase's microinverters are enjoying solid demand with rising solar rooftop installations. It can capture larger shares of the booming solar market with its latest innovations.
Per the Zacks analyst, Hawaiian Electric's systematic investments in utility infrastructure development help it to meet increasing consumer demand.
New Downgrades/h6
The Zacks analyst is concerned about contraction in fuel margins, which continues to hurt ExxonMobil's downstream business. Moreover, soft energy demand hurts the firm's upstream operation.
The Zacks analyst expects lower refining margins to affect BP's profit levels. Moreover, massive debt is likely to constraint its financial flexibility.
Per the Zacks analyst, BlackRock's restructuring efforts to modify the size and shape of its workforce will likely lead to higher expenses. Thus, elevated costs are expected to hurt the bottom line.
The Zacks analyst is concerned about contraction in fuel margins, which continues to hurt ExxonMobil's downstream business. Moreover, soft energy demand hurts the firm's upstream operation.
The Zacks analyst expects lower refining margins to affect BP's profit levels. Moreover, massive debt is likely to constraint its financial flexibility.
Per the Zacks analyst, BlackRock's restructuring efforts to modify the size and shape of its workforce will likely lead to higher expenses. Thus, elevated costs are expected to hurt the bottom line.
undefined Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.